Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020

GlobeNewswire May 6, 2020

Evolus Provides Strategic Business Update

GlobeNewswire April 16, 2020

Evolus Provides Update on International Trade Commission (ITC) Case

GlobeNewswire March 4, 2020

Evolus to Participate in Barclays 2020 Global Healthcare Conference

GlobeNewswire March 3, 2020

Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

GlobeNewswire February 25, 2020

Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 13, 2020

Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020

GlobeNewswire February 12, 2020

Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow's Feet Lines Published in Dermatologic Surgery

GlobeNewswire January 27, 2020

Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

GlobeNewswire January 9, 2020

Evolus to Participate in Stifel Healthcare Conference

GlobeNewswire November 7, 2019

Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire November 4, 2019

Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019

GlobeNewswire October 28, 2019

Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva(TM) (prabotulinumtoxinA) to Customers in Canada

GlobeNewswire October 16, 2019

Evolus Receives Approval for Nuceiva(TM) in the European Union

GlobeNewswire October 1, 2019

Evolus will Participate in Cantor Global Healthcare Conference

GlobeNewswire September 18, 2019

Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

GlobeNewswire September 4, 2019

Evolus to Participate in Two Upcoming Investor Conferences

GlobeNewswire August 22, 2019

Evolus Reports Second Quarter 2019 Financial Results

GlobeNewswire August 12, 2019

Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019

GlobeNewswire August 1, 2019

Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

GlobeNewswire July 15, 2019